ENLV
Enlivex Therapeutics Ltd
NASDAQ: ENLV · HEALTHCARE · BIOTECHNOLOGY
$0.73
-1.56% today
Updated 2026-06-02
Market cap
$171.15M
P/E ratio
0.03
P/S ratio
—
EPS (TTM)
$25.48
Dividend yield
—
52W range
$1 – $2
Volume
0.7M
WallStSmart proprietary scores
36
out of 100
Grade: D
Sell
Investment rating
4.3
Growth
C8.5
Quality
A5.0
Profitability
C+6.7
Valuation
B3/9
Piotroski F-Score
Weak
4.5
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$20.00
+2630.75%
12-Month target
$1.02
+39.27%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 4.50 — safe zone
+ ROE 126.20% — strong efficiency
+ Debt/equity 0.00x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-2.91M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net income | $-31.06M | $-29.07M | $-15.01M | $1.24B | $1.24B |
| EPS | — | — | — | — | $25.48 |
| Free cash flow | $-32.08M | $-23.76M | $-13.11M | $-10.48M | $-2.91M |
| Profit margin | — | — | — | — | — |
Peer comparison
Smart narrative
Enlivex Therapeutics Ltd trades at $0.73. representing a P/E of 0.03x trailing earnings. Our Smart Value Score of 36/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 4.50, it sits in the safe zone.
Frequently asked questions
What is Enlivex Therapeutics Ltd's stock price?
Enlivex Therapeutics Ltd (ENLV) trades at $0.73, on a P/E of 0.0x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Enlivex Therapeutics Ltd overvalued?
Enlivex Therapeutics Ltd carries a Smart Value Score of 36/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Enlivex Therapeutics Ltd (ENLV)?
The 12-month analyst consensus target is $20.00, about 2630.7% above the current $0.73. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Enlivex Therapeutics Ltd's Altman Z-Score is 4.50, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio—
ROE126.20%
Beta1.47
50D MA$0.85
200D MA$0.99
Shares out0.24B
Float0.06B
Short ratio—
Avg volume0.7M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—